Leemore Dafny is the Bruce V. Rauner Professor of Business Administration at the Harvard Business School, and a member of the faculty of the Kennedy School of Government. Prior to joining Harvard in 2016, she served as Director of Health Enterprise Management, Herman Smith Professor of Hospital and Health Services Management, and a professor of strategy at the Kellogg School of Management at Northwestern University.
Professor Dafny’s research examines competitive interactions among payers and providers of health care services, and the intersection of industry and public policy. Her work has been published in academic journals such as The American Economic Review and The New England Journal of Medicine, and featured in popular media such as The New York Times and The Wall Street Journal. Current projects include studies of consolidation in the U.S. hospital industry and the kidney dialysis industry, products and pricing on the public health insurance exchanges, co-payment coupons for prescription drugs, and the implications of for-profit ownership of insurance companies.
Professor Dafny graduated summa cum laude from Harvard College and worked as a consultant with McKinsey & Company prior to earning her PhD in economics from the Massachusetts Institute of Technology. She has won several teaching awards as well as Kellogg’s leading research prize, the Stanley Reiter Best Paper Award. Professor Dafny is a research associate of the National Bureau of Economic Research, an Associate Editor of Management Science, and a board member of the American Society of Health Economists and the Health Care Cost Institute.
Professor Dafny’s expertise spans both the public and private sectors. She serves on the Panel of Health Advisers for the Congressional Budget Office. In 2012–2013, she was Deputy Director for Health Care and Antitrust in the Bureau of Economics at the Federal Trade Commission. She also advises companies, government agencies, and nonprofits on a variety of issues including antitrust matters, strategic decisions, and public policy.
Three components for treating the unhealthy, uncompetitive U.S. health care market — beginning with a buyer’s revolt.
Clip by Leemore Dafny, David Lansky, Robert Galvin & Lynn Garbee
The companies most capable of leading transformation in health care coverage are the ones that least need to.
Clip by David Lansky, Robert Galvin, Lynn Garbee & Leemore Dafny
Why are employers hesitating? What do they value and want to invest in when it comes to health care payment plans?
Interview by Robert Galvin & Leemore Dafny
Will Amazon–Berkshire Hathaway–JP Morgan and CVS-Aetna change the health care game? To one health care employer purchaser, these announcements feel a lot like Groundhog Day.
What might one of the largest mergers in history mean for the health care delivery system?
Health care stakeholders are not aligned in important goals and in large part are not working together to achieve value-based care, according to the NEJM Catalyst Insights Council. They are waiting on government regulators to change the payment model — including, possibly, single-payer health care.
“What we aim to do is to create something akin to a public utility that is going to put public good first.”
Clip by Lynn Garbee, Robert Galvin & Leemore Dafny
Payers need to break out of their insular way of thinking.
We can’t get what we want in payment reform if we’re not clear about what that is.
Clip by Lynn Garbee & Leemore Dafny
What payers would like to see when it comes to engagement in value-based reimbursement and building healthier outcomes.